{
  "functional_evidence_assessment": [
    {
      "variant_id": {
        "Gene": "LRRK2",
        "Protein_Change": {
          "ref": "I",
          "alt": "V",
          "position": "1122"
        },
        "variant_string_id": "LRRK2 I1122V"
      },
      "functional_evidence_aim": "Pathogenic",
      "assessment_steps": [
        {
          "step_name": "Step 1: Define the disease mechanism",
          "extracted_paper_info": "Dominant mutations in the LRRK2 gene are a common cause of inherited Parkinson's disease (PD), associated with loss of nigral neurons and variable protein inclusion pathology. Mutant dardarin triggers cell loss and inclusion body formation, which are relevant to human disease.",
          "judgment": "Yes",
          "reasoning": "The paper clearly defines the disease mechanism as neuronal loss and protein inclusion pathology in PD, linking LRRK2 mutations to these phenotypes."
        },
        {
          "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
          "extracted_paper_info": "The study uses cellular assays to assess inclusion body formation and cell toxicity in multiple cell lines (COS7, HEK293, SH-SY5Y) and primary rat cortical neurons, reflecting phenotypes relevant to PD pathogenesis.",
          "judgment": "Yes",
          "reasoning": "The general class of assays (cellular phenotype assays for inclusion bodies and toxicity) effectively models aspects of PD pathogenesis, such as protein misfolding and neuronal loss.",
          "next_step_or_outcome": "Proceed to Step 3"
        },
        {
          "step_name": "Step 3a: Basic Controls and Replicates",
          "extracted_paper_info": "Wild-type dardarin is used as a negative control, and multiple pathogenic mutants are tested. Experiments are performed with replicate transfections (n=4) and repeated across multiple cell types.",
          "judgment": "Yes",
          "reasoning": "Both wild-type (negative) and mutant (positive) controls are included, and replicates are explicitly mentioned (e.g., n=4 replicate transfections, multiple experiments).",
          "next_step_or_outcome": "Proceed to Step 3c"
        },
        {
          "step_name": "Step 3c: Variant Controls",
          "extracted_paper_info": "Multiple known pathogenic variants (I1122V, R1441C, Y1699C, G2019S, I2020T) are tested alongside wild-type dardarin, but their classification independent of PS3/BS3 is not specified.",
          "judgment": "No",
          "reasoning": "While multiple pathogenic variants are used, the paper does not confirm if these variants reach P/LP criteria without relying on PS3/BS3 evidence.",
          "next_step_or_outcome": "Max PS3_supporting"
        }
      ],
      "final_evidence_strength": {
        "type": "Pathogenic",
        "strength": "PS3_supporting"
      },
      "overall_conclusion": "The functional evidence for LRRK2 I1122V supports pathogenicity at a supporting level (PS3_supporting) due to demonstrated inclusion body formation and toxicity in cellular assays, with appropriate controls and replicates, but lacking independent variant control classification."
    },
    {
      "variant_id": {
        "Gene": "LRRK2",
        "Protein_Change": {
          "ref": "R",
          "alt": "C",
          "position": "1441"
        },
        "variant_string_id": "LRRK2 R1441C"
      },
      "functional_evidence_aim": "Pathogenic",
      "assessment_steps": [
        {
          "step_name": "Step 1: Define the disease mechanism",
          "extracted_paper_info": "Dominant mutations in the LRRK2 gene are a common cause of inherited Parkinson's disease (PD), associated with loss of nigral neurons and variable protein inclusion pathology. Mutant dardarin triggers cell loss and inclusion body formation, which are relevant to human disease.",
          "judgment": "Yes",
          "reasoning": "The paper clearly defines the disease mechanism as neuronal loss and protein inclusion pathology in PD, linking LRRK2 mutations to these phenotypes."
        },
        {
          "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
          "extracted_paper_info": "The study uses cellular assays to assess inclusion body formation and cell toxicity in multiple cell lines (COS7, HEK293, SH-SY5Y) and primary rat cortical neurons, reflecting phenotypes relevant to PD pathogenesis.",
          "judgment": "Yes",
          "reasoning": "The general class of assays (cellular phenotype assays for inclusion bodies and toxicity) effectively models aspects of PD pathogenesis, such as protein misfolding and neuronal loss.",
          "next_step_or_outcome": "Proceed to Step 3"
        },
        {
          "step_name": "Step 3a: Basic Controls and Replicates",
          "extracted_paper_info": "Wild-type dardarin is used as a negative control, and multiple pathogenic mutants are tested. Experiments are performed with replicate transfections (n=4) and repeated across multiple cell types.",
          "judgment": "Yes",
          "reasoning": "Both wild-type (negative) and mutant (positive) controls are included, and replicates are explicitly mentioned (e.g., n=4 replicate transfections, multiple experiments).",
          "next_step_or_outcome": "Proceed to Step 3c"
        },
        {
          "step_name": "Step 3c: Variant Controls",
          "extracted_paper_info": "Multiple known pathogenic variants (I1122V, R1441C, Y1699C, G2019S, I2020T) are tested alongside wild-type dardarin, but their classification independent of PS3/BS3 is not specified.",
          "judgment": "No",
          "reasoning": "While multiple pathogenic variants are used, the paper does not confirm if these variants reach P/LP criteria without relying on PS3/BS3 evidence.",
          "next_step_or_outcome": "Max PS3_supporting"
        }
      ],
      "final_evidence_strength": {
        "type": "Pathogenic",
        "strength": "PS3_supporting"
      },
      "overall_conclusion": "The functional evidence for LRRK2 R1441C supports pathogenicity at a supporting level (PS3_supporting) due to demonstrated inclusion body formation and toxicity in cellular assays, with appropriate controls and replicates, but lacking independent variant control classification."
    },
    {
      "variant_id": {
        "Gene": "LRRK2",
        "Protein_Change": {
          "ref": "Y",
          "alt": "C",
          "position": "1699"
        },
        "variant_string_id": "LRRK2 Y1699C"
      },
      "functional_evidence_aim": "Pathogenic",
      "assessment_steps": [
        {
          "step_name": "Step 1: Define the disease mechanism",
          "extracted_paper_info": "Dominant mutations in the LRRK2 gene are a common cause of inherited Parkinson's disease (PD), associated with loss of nigral neurons and variable protein inclusion pathology. Mutant dardarin triggers cell loss and inclusion body formation, which are relevant to human disease.",
          "judgment": "Yes",
          "reasoning": "The paper clearly defines the disease mechanism as neuronal loss and protein inclusion pathology in PD, linking LRRK2 mutations to these phenotypes."
        },
        {
          "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
          "extracted_paper_info": "The study uses cellular assays to assess inclusion body formation and cell toxicity in multiple cell lines (COS7, HEK293, SH-SY5Y) and primary rat cortical neurons, reflecting phenotypes relevant to PD pathogenesis.",
          "judgment": "Yes",
          "reasoning": "The general class of assays (cellular phenotype assays for inclusion bodies and toxicity) effectively models aspects of PD pathogenesis, such as protein misfolding and neuronal loss.",
          "next_step_or_outcome": "Proceed to Step 3"
        },
        {
          "step_name": "Step 3a: Basic Controls and Replicates",
          "extracted_paper_info": "Wild-type dardarin is used as a negative control, and multiple pathogenic mutants are tested. Experiments are performed with replicate transfections (n=4) and repeated across multiple cell types.",
          "judgment": "Yes",
          "reasoning": "Both wild-type (negative) and mutant (positive) controls are included, and replicates are explicitly mentioned (e.g., n=4 replicate transfections, multiple experiments).",
          "next_step_or_outcome": "Proceed to Step 3c"
        },
        {
          "step_name": "Step 3c: Variant Controls",
          "extracted_paper_info": "Multiple known pathogenic variants (I1122V, R1441C, Y1699C, G2019S, I2020T) are tested alongside wild-type dardarin, but their classification independent of PS3/BS3 is not specified.",
          "judgment": "No",
          "reasoning": "While multiple pathogenic variants are used, the paper does not confirm if these variants reach P/LP criteria without relying on PS3/BS3 evidence.",
          "next_step_or_outcome": "Max PS3_supporting"
        }
      ],
      "final_evidence_strength": {
        "type": "Pathogenic",
        "strength": "PS3_supporting"
      },
      "overall_conclusion": "The functional evidence for LRRK2 Y1699C supports pathogenicity at a supporting level (PS3_supporting) due to demonstrated inclusion body formation and toxicity in cellular assays, with appropriate controls and replicates, but lacking independent variant control classification."
    },
    {
      "variant_id": {
        "Gene": "LRRK2",
        "Protein_Change": {
          "ref": "G",
          "alt": "S",
          "position": "2019"
        },
        "variant_string_id": "LRRK2 G2019S"
      },
      "functional_evidence_aim": "Pathogenic",
      "assessment_steps": [
        {
          "step_name": "Step 1: Define the disease mechanism",
          "extracted_paper_info": "Dominant mutations in the LRRK2 gene are a common cause of inherited Parkinson's disease (PD), associated with loss of nigral neurons and variable protein inclusion pathology. Mutant dardarin triggers cell loss and inclusion body formation, which are relevant to human disease.",
          "judgment": "Yes",
          "reasoning": "The paper clearly defines the disease mechanism as neuronal loss and protein inclusion pathology in PD, linking LRRK2 mutations to these phenotypes."
        },
        {
          "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
          "extracted_paper_info": "The study uses cellular assays to assess inclusion body formation and cell toxicity in multiple cell lines (COS7, HEK293, SH-SY5Y) and primary rat cortical neurons, reflecting phenotypes relevant to PD pathogenesis. Additionally, in vitro autophosphorylation assays show increased kinase activity for G2019S.",
          "judgment": "Yes",
          "reasoning": "The general class of assays (cellular phenotype and kinase activity assays) effectively models aspects of PD pathogenesis, such as protein misfolding, neuronal loss, and altered kinase activity.",
          "next_step_or_outcome": "Proceed to Step 3"
        },
        {
          "step_name": "Step 3a: Basic Controls and Replicates",
          "extracted_paper_info": "Wild-type dardarin is used as a negative control, and multiple pathogenic mutants are tested. Experiments are performed with replicate transfections (n=4) and repeated across multiple cell types. Autophosphorylation assays are quantified from quadruplicate samples.",
          "judgment": "Yes",
          "reasoning": "Both wild-type (negative) and mutant (positive) controls are included, and replicates are explicitly mentioned (e.g., n=4 replicate transfections, quadruplicate samples for kinase assays).",
          "next_step_or_outcome": "Proceed to Step 3c"
        },
        {
          "step_name": "Step 3c: Variant Controls",
          "extracted_paper_info": "Multiple known pathogenic variants (I1122V, R1441C, Y1699C, G2019S, I2020T) are tested alongside wild-type dardarin, but their classification independent of PS3/BS3 is not specified.",
          "judgment": "No",
          "reasoning": "While multiple pathogenic variants are used, the paper does not confirm if these variants reach P/LP criteria without relying on PS3/BS3 evidence.",
          "next_step_or_outcome": "Max PS3_supporting"
        }
      ],
      "final_evidence_strength": {
        "type": "Pathogenic",
        "strength": "PS3_supporting"
      },
      "overall_conclusion": "The functional evidence for LRRK2 G2019S supports pathogenicity at a supporting level (PS3_supporting) due to demonstrated inclusion body formation, toxicity, and increased kinase activity in cellular and biochemical assays, with appropriate controls and replicates, but lacking independent variant control classification."
    },
    {
      "variant_id": {
        "Gene": "LRRK2",
        "Protein_Change": {
          "ref": "I",
          "alt": "T",
          "position": "2020"
        },
        "variant_string_id": "LRRK2 I2020T"
      },
      "functional_evidence_aim": "Pathogenic",
      "assessment_steps": [
        {
          "step_name": "Step 1: Define the disease mechanism",
          "extracted_paper_info": "Dominant mutations in the LRRK2 gene are a common cause of inherited Parkinson's disease (PD), associated with loss of nigral neurons and variable protein inclusion pathology. Mutant dardarin triggers cell loss and inclusion body formation, which are relevant to human disease.",
          "judgment": "Yes",
          "reasoning": "The paper clearly defines the disease mechanism as neuronal loss and protein inclusion pathology in PD, linking LRRK2 mutations to these phenotypes."
        },
        {
          "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
          "extracted_paper_info": "The study uses cellular assays to assess inclusion body formation and cell toxicity in multiple cell lines (COS7, HEK293, SH-SY5Y) and primary rat cortical neurons, reflecting phenotypes relevant to PD pathogenesis.",
          "judgment": "Yes",
          "reasoning": "The general class of assays (cellular phenotype assays for inclusion bodies and toxicity) effectively models aspects of PD pathogenesis, such as protein misfolding and neuronal loss.",
          "next_step_or_outcome": "Proceed to Step 3"
        },
        {
          "step_name": "Step 3a: Basic Controls and Replicates",
          "extracted_paper_info": "Wild-type dardarin is used as a negative control, and multiple pathogenic mutants are tested. Experiments are performed with replicate transfections (n=4) and repeated across multiple cell types.",
          "judgment": "Yes",
          "reasoning": "Both wild-type (negative) and mutant (positive) controls are included, and replicates are explicitly mentioned (e.g., n=4 replicate transfections, multiple experiments).",
          "next_step_or_outcome": "Proceed to Step 3c"
        },
        {
          "step_name": "Step 3c: Variant Controls",
          "extracted_paper_info": "Multiple known pathogenic variants (I1122V, R1441C, Y1699C, G2019S, I2020T) are tested alongside wild-type dardarin, but their classification independent of PS3/BS3 is not specified.",
          "judgment": "No",
          "reasoning": "While multiple pathogenic variants are used, the paper does not confirm if these variants reach P/LP criteria without relying on PS3/BS3 evidence.",
          "next_step_or_outcome": "Max PS3_supporting"
        }
      ],
      "final_evidence_strength": {
        "type": "Pathogenic",
        "strength": "PS3_supporting"
      },
      "overall_conclusion": "The functional evidence for LRRK2 I2020T supports pathogenicity at a supporting level (PS3_supporting) due to demonstrated inclusion body formation and toxicity in cellular assays, with appropriate controls and replicates, but lacking independent variant control classification."
    }
  ]
}